APO Research
Talk to an analyst

APO RESEARCH · REPORT

Biosimilar Monoclonal Antibodies

Monoclonal antibodies (mAb) are antibodies produced by using identical immune cells that are clones of one unique parent cell. Since monoclonal antibodies are produced from clones of only one parent cell, all monoclonal antibodies produced by the parent cell are the same due to which, they are called biosimilar monoclonal antibodies.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Monoclonal antibodies (mAb) are antibodies produced by using identical immune cells that are clones of one unique parent cell. Since monoclonal antibodies are produced from clones of only one parent cell, all monoclonal antibodies produced by the parent cell are the same due to which, they are called biosimilar monoclonal antibodies.

Biosimilar Monoclonal Antibodies refer to the biologic medical product that are almost an identical copy of the original monoclonal antibodies but manufactured by a different company.

Selected research

Market Outlook & Growth Opportunities

Global Biosimilar Monoclonal Antibodies Market Outlook and Growth Opportunities 2026

21 December 2025195 pages

Choose your research edition.

Industry ResearchBiosimilar Monoclonal Antibodies Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Biosimilar Monoclonal Antibodies Industry Growth and Trends Forecast to 203293 pages · $3,450 USDMarket StructureGlobal Biosimilar Monoclonal Antibodies Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Biosimilar Monoclonal Antibodies Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Biosimilar Monoclonal Antibodies Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

Monoclonal antibodies (mAb) are antibodies produced by using identical immune cells that are clones of one unique parent cell. Since monoclonal antibodies are produced from clones of only one parent cell, all monoclonal antibodies produced by the parent cell are the same due to which, they are called biosimilar monoclonal antibodies.

Biosimilar Monoclonal Antibodies refer to the biologic medical product that are almost an identical copy of the original monoclonal antibodies but manufactured by a different company.

Global Biosimilar Monoclonal Antibodies key players include Celltrion, 3SBIO, Pfizer (Hospira), Novartis (Sandoz), etc. Global top four manufacturers hold a share nearly 85%.

Read the full market overview

Europe is the largest market, with a share about 40%, followed by China, and United States, both have a share about 50 percent.

In terms of product, Infliximab is the largest segment, with a share nearly 40%. And in terms of application, the largest application is Autoimmune Disease, followed by Oncology, etc.

This report provides an overview of the global Biosimilar Monoclonal Antibodies market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Biosimilar Monoclonal Antibodies and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Biosimilar Monoclonal Antibodies sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Biosimilar Monoclonal Antibodies market size, projected growth trends, production technologies, key applications, and end-use industries.

Biosimilar Monoclonal Antibodies Segment by Company

Celltrion

Pfizer (Hospira)

3SBIO

Novartis (Sandoz)

Dr Reddy’s

Celgen Biopharma

Cadila Healthcare

Hisun Pharma

Torrent Pharmaceuticals

Biosimilar Monoclonal Antibodies Segment by Type

Infliximab

Rituximab

Trastuzumab

Adalimumab

Other

Biosimilar Monoclonal Antibodies Segment by Application

Oncology

Autoimmune Disease

Other

Biosimilar Monoclonal Antibodies Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Biosimilar Monoclonal Antibodies status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Biosimilar Monoclonal Antibodies market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Biosimilar Monoclonal Antibodies significant trends, drivers, influence factors in global and regions.

6. To analyze Biosimilar Monoclonal Antibodies competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biosimilar Monoclonal Antibodies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Biosimilar Monoclonal Antibodies and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biosimilar Monoclonal Antibodies.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Biosimilar Monoclonal Antibodies market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Biosimilar Monoclonal Antibodies industry.

Chapter 3: Detailed analysis of Biosimilar Monoclonal Antibodies manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Biosimilar Monoclonal Antibodies in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Biosimilar Monoclonal Antibodies in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Biosimilar Monoclonal Antibodies Industry Trends Table 2. Biosimilar Monoclonal Antibodies Industry Drivers Table 3. Biosimilar Monoclonal Antibodies Industry Opportunities and Challenges Table 4. Biosimilar Monoclonal Antibodies Industry Restraints Table 5. Global Biosimilar Monoclonal Antibodies Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Biosimilar Monoclonal Antibodies Revenue Share by Company (2021-2026) Table 7. Global Biosimilar Monoclonal Antibodies Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Biosimilar Monoclonal Antibodies Sales Volume Share by Company (2021-2026) Table 9. Global Biosimilar Monoclonal Antibodies Average Price (USD/Unit) of Company (2021-2026) Table 10. Global Biosimilar Monoclonal Antibodies Company Ranking, (2024-2026) & (USD Million) Table 11. Global Biosimilar Monoclonal Antibodies Key Company Manufacturing Base & Headquarters Table 12. Global Biosimilar Monoclonal Antibodies Company, Product Type & Application Table 13. Global Biosimilar Monoclonal Antibodies Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Biosimilar Monoclonal Antibodies by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Infliximab Table 18. Significant Companies of Rituximab Table 19. Significant Companies of Trastuzumab Table 20. Significant Companies of Adalimumab Table 21. Significant Companies of Other Table 22. Global Biosimilar Monoclonal Antibodies Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global Biosimilar Monoclonal Antibodies Sales Volume by Type (2021-2026) & (K Units) Table 24. Global Biosimilar Monoclonal Antibodies Sales Volume by Type (2027-2032) & (K Units) Table 25. Global Biosimilar Monoclonal Antibodies Sales Volume Share by Type (2021-2026) Table 26. Global Biosimilar Monoclonal Antibodies Sales Volume Share by Type (2027-2032) Table 27. Global Biosimilar Monoclonal Antibodies Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Biosimilar Monoclonal Antibodies Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Biosimilar Monoclonal Antibodies Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Biosimilar Monoclonal Antibodies Sales Value Share by Type (2021-2026) Table 31. Global Biosimilar Monoclonal Antibodies Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Oncology Table 33. Significant Companies of Autoimmune Disease Table 34. Significant Companies of Other Table 35. Global Biosimilar Monoclonal Antibodies Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Biosimilar Monoclonal Antibodies Sales Volume by Application (2021-2026) & (K Units) Table 37. Global Biosimilar Monoclonal Antibodies Sales Volume by Application (2027-2032) & (K Units) Table 38. Global Biosimilar Monoclonal Antibodies Sales Volume Share by Application (2021-2026) Table 39. Global Biosimilar Monoclonal Antibodies Sales Volume Share by Application (2027-2032) Table 40. Global Biosimilar Monoclonal Antibodies Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Biosimilar Monoclonal Antibodies Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Biosimilar Monoclonal Antibodies Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Biosimilar Monoclonal Antibodies Sales Value Share by Application (2021-2026) Table 44. Global Biosimilar Monoclonal Antibodies Sales Value Share by Application (2027-2032) Table 45. Global Biosimilar Monoclonal Antibodies Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global Biosimilar Monoclonal Antibodies Sales by Region (2021-2026) & (K Units) Table 47. Global Biosimilar Monoclonal Antibodies Sales Market Share by Region (2021-2026) Table 48. Global Biosimilar Monoclonal Antibodies Sales by Region (2027-2032) & (K Units) Table 49. Global Biosimilar Monoclonal Antibodies Sales Market Share by Region (2027-2032) Table 50. Global Biosimilar Monoclonal Antibodies Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Biosimilar Monoclonal Antibodies Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Biosimilar Monoclonal Antibodies Sales Value Share by Region (2021-2026) Table 53. Global Biosimilar Monoclonal Antibodies Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Biosimilar Monoclonal Antibodies Sales Value Share by Region (2027-2032) Table 55. Global Biosimilar Monoclonal Antibodies Market Average Price (USD/Unit) by Region (2021-2026) Table 56. Global Biosimilar Monoclonal Antibodies Market Average Price (USD/Unit) by Region (2027-2032) Table 57. Global Biosimilar Monoclonal Antibodies Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Global Biosimilar Monoclonal Antibodies Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Biosimilar Monoclonal Antibodies Sales by Country (2021-2026) & (K Units) Table 60. Global Biosimilar Monoclonal Antibodies Sales Market Share by Country (2021-2026) Table 61. Global Biosimilar Monoclonal Antibodies Sales by Country (2027-2032) & (K Units) Table 62. Global Biosimilar Monoclonal Antibodies Sales Market Share by Country (2027-2032) Table 63. Global Biosimilar Monoclonal Antibodies Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Biosimilar Monoclonal Antibodies Sales Value Market Share by Country (2021-2026) Table 65. Global Biosimilar Monoclonal Antibodies Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Biosimilar Monoclonal Antibodies Sales Value Market Share by Country (2027-2032) Table 67. Celltrion Company Information Table 68. Celltrion Business Overview Table 69. Celltrion Biosimilar Monoclonal Antibodies Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 70. Celltrion Biosimilar Monoclonal Antibodies Product Portfolio Table 71. Celltrion Recent Development Table 72. Pfizer (Hospira) Company Information Table 73. Pfizer (Hospira) Business Overview Table 74. Pfizer (Hospira) Biosimilar Monoclonal Antibodies Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 75. Pfizer (Hospira) Biosimilar Monoclonal Antibodies Product Portfolio Table 76. Pfizer (Hospira) Recent Development Table 77. 3SBIO Company Information Table 78. 3SBIO Business Overview Table 79. 3SBIO Biosimilar Monoclonal Antibodies Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 80. 3SBIO Biosimilar Monoclonal Antibodies Product Portfolio Table 81. 3SBIO Recent Development Table 82. Novartis (Sandoz) Company Information Table 83. Novartis (Sandoz) Business Overview Table 84. Novartis (Sandoz) Biosimilar Monoclonal Antibodies Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 85. Novartis (Sandoz) Biosimilar Monoclonal Antibodies Product Portfolio Table 86. Novartis (Sandoz) Recent Development Table 87. Dr Reddy’s Company Information Table 88. Dr Reddy’s Business Overview Table 89. Dr Reddy’s Biosimilar Monoclonal Antibodies Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 90. Dr Reddy’s Biosimilar Monoclonal Antibodies Product Portfolio Table 91. Dr Reddy’s Recent Development Table 92. Celgen Biopharma Company Information Table 93. Celgen Biopharma Business Overview Table 94. Celgen Biopharma Biosimilar Monoclonal Antibodies Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 95. Celgen Biopharma Biosimilar Monoclonal Antibodies Product Portfolio Table 96. Celgen Biopharma Recent Development Table 97. Cadila Healthcare Company Information Table 98. Cadila Healthcare Business Overview Table 99. Cadila Healthcare Biosimilar Monoclonal Antibodies Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 100. Cadila Healthcare Biosimilar Monoclonal Antibodies Product Portfolio Table 101. Cadila Healthcare Recent Development Table 102. Hisun Pharma Company Information Table 103. Hisun Pharma Business Overview Table 104. Hisun Pharma Biosimilar Monoclonal Antibodies Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 105. Hisun Pharma Biosimilar Monoclonal Antibodies Product Portfolio Table 106. Hisun Pharma Recent Development Table 107. Torrent Pharmaceuticals Company Information Table 108. Torrent Pharmaceuticals Business Overview Table 109. Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 110. Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Product Portfolio Table 111. Torrent Pharmaceuticals Recent Development Table 112. Key Raw Materials Table 113. Raw Materials Key Suppliers Table 114. Biosimilar Monoclonal Antibodies Distributors List Table 115. Biosimilar Monoclonal Antibodies Customers List Table 116. Research Programs/Design for This Report Table 117. Authors List of This Report Table 118. Secondary Sources Table 119. Primary Sources List of Figures Figure 1. Biosimilar Monoclonal Antibodies Product Image Figure 2. Global Biosimilar Monoclonal Antibodies Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Biosimilar Monoclonal Antibodies Sales Value (2021-2032) & (US$ Million) Figure 4. Global Biosimilar Monoclonal Antibodies Sales (2021-2032) & (K Units) Figure 5. Global Biosimilar Monoclonal Antibodies Sales Average Price (USD/Unit) & (2021-2032) Figure 6. Global Biosimilar Monoclonal Antibodies Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Infliximab Image Figure 10. Rituximab Image Figure 11. Trastuzumab Image Figure 12. Adalimumab Image Figure 13. Other Image Figure 14. Global Biosimilar Monoclonal Antibodies Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Biosimilar Monoclonal Antibodies Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Biosimilar Monoclonal Antibodies Sales Volume Share by Type (2021-2032) Figure 17. Global Biosimilar Monoclonal Antibodies Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Biosimilar Monoclonal Antibodies Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Biosimilar Monoclonal Antibodies Sales Value Share by Type (2021-2032) Figure 20. Oncology Image Figure 21. Autoimmune Disease Image Figure 22. Other Image Figure 23. Global Biosimilar Monoclonal Antibodies Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Biosimilar Monoclonal Antibodies Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Biosimilar Monoclonal Antibodies Sales Volume Share by Application (2021-2032) Figure 26. Global Biosimilar Monoclonal Antibodies Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Biosimilar Monoclonal Antibodies Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Biosimilar Monoclonal Antibodies Sales Value Share by Application (2021-2032) Figure 29. Global Biosimilar Monoclonal Antibodies Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 30. Global Biosimilar Monoclonal Antibodies Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Biosimilar Monoclonal Antibodies Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Biosimilar Monoclonal Antibodies Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Biosimilar Monoclonal Antibodies Sales Value (2021-2032) & (US$ Million) Figure 34. North America Biosimilar Monoclonal Antibodies Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Biosimilar Monoclonal Antibodies Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Biosimilar Monoclonal Antibodies Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Biosimilar Monoclonal Antibodies Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Biosimilar Monoclonal Antibodies Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Biosimilar Monoclonal Antibodies Sales Value (2021-2032) & (US$ Million) Figure 40. South America Biosimilar Monoclonal Antibodies Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Biosimilar Monoclonal Antibodies Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Biosimilar Monoclonal Antibodies Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Biosimilar Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Biosimilar Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Biosimilar Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Biosimilar Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Biosimilar Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Biosimilar Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Biosimilar Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Biosimilar Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Biosimilar Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Biosimilar Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Biosimilar Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Biosimilar Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Biosimilar Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Biosimilar Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Biosimilar Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Biosimilar Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Biosimilar Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Biosimilar Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Biosimilar Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Biosimilar Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Biosimilar Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Biosimilar Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Biosimilar Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Biosimilar Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Biosimilar Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Biosimilar Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Biosimilar Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Biosimilar Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Biosimilar Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Biosimilar Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Biosimilar Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Biosimilar Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Biosimilar Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Biosimilar Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Biosimilar Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Biosimilar Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Biosimilar Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Biosimilar Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Biosimilar Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Biosimilar Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Biosimilar Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Biosimilar Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Biosimilar Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Biosimilar Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Biosimilar Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Biosimilar Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Biosimilar Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Biosimilar Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Biosimilar Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Biosimilar Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Biosimilar Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Biosimilar Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Biosimilar Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Biosimilar Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Biosimilar Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Biosimilar Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Biosimilar Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Biosimilar Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Biosimilar Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Biosimilar Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Biosimilar Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Biosimilar Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Biosimilar Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Biosimilar Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Biosimilar Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Biosimilar Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Biosimilar Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Biosimilar Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Biosimilar Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Biosimilar Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Biosimilar Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Biosimilar Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Biosimilar Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Biosimilar Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Biosimilar Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Biosimilar Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Biosimilar Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Biosimilar Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Biosimilar Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Biosimilar Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Biosimilar Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Biosimilar Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Biosimilar Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Biosimilar Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Biosimilar Monoclonal Antibodies Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Biosimilar Monoclonal Antibodies Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • Infliximab
  • Rituximab
  • Trastuzumab
  • Adalimumab
  • Other
Applications
  • Oncology
  • Autoimmune Disease
  • Other
Companies covered
  • Celltrion
  • Pfizer (Hospira)
  • 3SBIO
  • Novartis (Sandoz)
  • Dr Reddy’s
  • Celgen Biopharma
  • Cadila Healthcare
  • Hisun Pharma
  • Torrent Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Biosimilar Monoclonal Antibodies Sales Value (2021-2032)
  4. 1.2.2 Global Biosimilar Monoclonal Antibodies Sales Volume (2021-2032)
  5. 1.2.3 Global Biosimilar Monoclonal Antibodies Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Biosimilar Monoclonal Antibodies Market Dynamics
  1. 2.1 Biosimilar Monoclonal Antibodies Industry Trends
  2. 2.2 Biosimilar Monoclonal Antibodies Industry Drivers
  3. 2.3 Biosimilar Monoclonal Antibodies Industry Opportunities and Challenges
  4. 2.4 Biosimilar Monoclonal Antibodies Industry Restraints
3 Biosimilar Monoclonal Antibodies Market by Company
  1. 3.1 Global Biosimilar Monoclonal Antibodies Company Revenue Ranking in 2025
  2. 3.2 Global Biosimilar Monoclonal Antibodies Revenue by Company (2021-2026)
  3. 3.3 Global Biosimilar Monoclonal Antibodies Sales Volume by Company (2021-2026)
  4. 3.4 Global Biosimilar Monoclonal Antibodies Average Price by Company (2021-2026)
  5. 3.5 Global Biosimilar Monoclonal Antibodies Company Ranking (2024-2026)
  6. 3.6 Global Biosimilar Monoclonal Antibodies Company Manufacturing Base and Headquarters
  7. 3.7 Global Biosimilar Monoclonal Antibodies Company Product Type and Application
  8. 3.8 Global Biosimilar Monoclonal Antibodies Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Biosimilar Monoclonal Antibodies Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Biosimilar Monoclonal Antibodies Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Biosimilar Monoclonal Antibodies Market by Type
  1. 4.1 Biosimilar Monoclonal Antibodies Type Introduction
  2. 4.1.1 Infliximab
  3. 4.1.2 Rituximab
  4. 4.1.3 Trastuzumab
  5. 4.1.4 Adalimumab
  6. 4.1.5 Other
  7. 4.2 Global Biosimilar Monoclonal Antibodies Sales Volume by Type
  8. 4.2.1 Global Biosimilar Monoclonal Antibodies Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Biosimilar Monoclonal Antibodies Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Biosimilar Monoclonal Antibodies Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Biosimilar Monoclonal Antibodies Sales Value by Type
  12. 4.3.1 Global Biosimilar Monoclonal Antibodies Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Biosimilar Monoclonal Antibodies Sales Value by Type (2021-2032)
  14. 4.3.3 Global Biosimilar Monoclonal Antibodies Sales Value Share by Type (2021-2032)
5 Biosimilar Monoclonal Antibodies Market by Application
  1. 5.1 Biosimilar Monoclonal Antibodies Application Introduction
  2. 5.1.1 Oncology
  3. 5.1.2 Autoimmune Disease
  4. 5.1.3 Other
  5. 5.2 Global Biosimilar Monoclonal Antibodies Sales Volume by Application
  6. 5.2.1 Global Biosimilar Monoclonal Antibodies Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Biosimilar Monoclonal Antibodies Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Biosimilar Monoclonal Antibodies Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Biosimilar Monoclonal Antibodies Sales Value by Application
  10. 5.3.1 Global Biosimilar Monoclonal Antibodies Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Biosimilar Monoclonal Antibodies Sales Value by Application (2021-2032)
  12. 5.3.3 Global Biosimilar Monoclonal Antibodies Sales Value Share by Application (2021-2032)
6 Biosimilar Monoclonal Antibodies Regional Sales and Value Analysis
  1. 6.1 Global Biosimilar Monoclonal Antibodies Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Biosimilar Monoclonal Antibodies Sales by Region (2021-2032)
  3. 6.2.1 Global Biosimilar Monoclonal Antibodies Sales by Region: 2021-2026
  4. 6.2.2 Global Biosimilar Monoclonal Antibodies Sales by Region (2027-2032)
  5. 6.3 Global Biosimilar Monoclonal Antibodies Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Biosimilar Monoclonal Antibodies Sales Value by Region (2021-2032)
  7. 6.4.1 Global Biosimilar Monoclonal Antibodies Sales Value by Region: 2021-2026
  8. 6.4.2 Global Biosimilar Monoclonal Antibodies Sales Value by Region (2027-2032)
  9. 6.5 Global Biosimilar Monoclonal Antibodies Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Biosimilar Monoclonal Antibodies Sales Value (2021-2032)
  12. 6.6.2 North America Biosimilar Monoclonal Antibodies Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Biosimilar Monoclonal Antibodies Sales Value (2021-2032)
  15. 6.7.2 Europe Biosimilar Monoclonal Antibodies Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Biosimilar Monoclonal Antibodies Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Biosimilar Monoclonal Antibodies Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Biosimilar Monoclonal Antibodies Sales Value (2021-2032)
  21. 6.9.2 South America Biosimilar Monoclonal Antibodies Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Biosimilar Monoclonal Antibodies Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Biosimilar Monoclonal Antibodies Sales Value Share by Country, 2025 VS 2032
7 Biosimilar Monoclonal Antibodies Country-level Sales and Value Analysis
  1. 7.1 Global Biosimilar Monoclonal Antibodies Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Biosimilar Monoclonal Antibodies Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Biosimilar Monoclonal Antibodies Sales by Country (2021-2032)
  4. 7.3.1 Global Biosimilar Monoclonal Antibodies Sales by Country (2021-2026)
  5. 7.3.2 Global Biosimilar Monoclonal Antibodies Sales by Country (2027-2032)
  6. 7.4 Global Biosimilar Monoclonal Antibodies Sales Value by Country (2021-2032)
  7. 7.4.1 Global Biosimilar Monoclonal Antibodies Sales Value by Country (2021-2026)
  8. 7.4.2 Global Biosimilar Monoclonal Antibodies Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Biosimilar Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Biosimilar Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Biosimilar Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Biosimilar Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Biosimilar Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Biosimilar Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Biosimilar Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Biosimilar Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Biosimilar Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Biosimilar Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Biosimilar Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Biosimilar Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Biosimilar Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Biosimilar Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Biosimilar Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Biosimilar Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Biosimilar Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Biosimilar Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Biosimilar Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Biosimilar Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Biosimilar Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Biosimilar Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Biosimilar Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Biosimilar Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Biosimilar Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Biosimilar Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Biosimilar Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Biosimilar Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Biosimilar Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Biosimilar Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Biosimilar Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Biosimilar Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Biosimilar Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Biosimilar Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Biosimilar Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Biosimilar Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Biosimilar Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Biosimilar Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Biosimilar Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Biosimilar Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Biosimilar Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Biosimilar Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Biosimilar Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Biosimilar Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Biosimilar Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Biosimilar Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Biosimilar Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Biosimilar Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Biosimilar Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Biosimilar Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Biosimilar Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Biosimilar Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Biosimilar Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Biosimilar Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Biosimilar Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Biosimilar Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Biosimilar Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Biosimilar Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Biosimilar Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Biosimilar Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Biosimilar Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Biosimilar Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Biosimilar Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Biosimilar Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Biosimilar Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Biosimilar Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Biosimilar Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Biosimilar Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Biosimilar Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Biosimilar Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Biosimilar Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Biosimilar Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Biosimilar Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Biosimilar Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Biosimilar Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Biosimilar Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Biosimilar Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Biosimilar Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Biosimilar Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Biosimilar Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Biosimilar Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Biosimilar Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Biosimilar Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Biosimilar Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Celltrion
  2. 8.1.1 Celltrion Company Information
  3. 8.1.2 Celltrion Business Overview
  4. 8.1.3 Celltrion Biosimilar Monoclonal Antibodies Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Celltrion Biosimilar Monoclonal Antibodies Product Portfolio
  6. 8.1.5 Celltrion Recent Developments
  7. 8.2 Pfizer (Hospira)
  8. 8.2.1 Pfizer (Hospira) Company Information
  9. 8.2.2 Pfizer (Hospira) Business Overview
  10. 8.2.3 Pfizer (Hospira) Biosimilar Monoclonal Antibodies Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Pfizer (Hospira) Biosimilar Monoclonal Antibodies Product Portfolio
  12. 8.2.5 Pfizer (Hospira) Recent Developments
  13. 8.3 3SBIO
  14. 8.3.1 3SBIO Company Information
  15. 8.3.2 3SBIO Business Overview
  16. 8.3.3 3SBIO Biosimilar Monoclonal Antibodies Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 3SBIO Biosimilar Monoclonal Antibodies Product Portfolio
  18. 8.3.5 3SBIO Recent Developments
  19. 8.4 Novartis (Sandoz)
  20. 8.4.1 Novartis (Sandoz) Company Information
  21. 8.4.2 Novartis (Sandoz) Business Overview
  22. 8.4.3 Novartis (Sandoz) Biosimilar Monoclonal Antibodies Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Novartis (Sandoz) Biosimilar Monoclonal Antibodies Product Portfolio
  24. 8.4.5 Novartis (Sandoz) Recent Developments
  25. 8.5 Dr Reddy’s
  26. 8.5.1 Dr Reddy’s Company Information
  27. 8.5.2 Dr Reddy’s Business Overview
  28. 8.5.3 Dr Reddy’s Biosimilar Monoclonal Antibodies Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Dr Reddy’s Biosimilar Monoclonal Antibodies Product Portfolio
  30. 8.5.5 Dr Reddy’s Recent Developments
  31. 8.6 Celgen Biopharma
  32. 8.6.1 Celgen Biopharma Company Information
  33. 8.6.2 Celgen Biopharma Business Overview
  34. 8.6.3 Celgen Biopharma Biosimilar Monoclonal Antibodies Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Celgen Biopharma Biosimilar Monoclonal Antibodies Product Portfolio
  36. 8.6.5 Celgen Biopharma Recent Developments
  37. 8.7 Cadila Healthcare
  38. 8.7.1 Cadila Healthcare Company Information
  39. 8.7.2 Cadila Healthcare Business Overview
  40. 8.7.3 Cadila Healthcare Biosimilar Monoclonal Antibodies Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Cadila Healthcare Biosimilar Monoclonal Antibodies Product Portfolio
  42. 8.7.5 Cadila Healthcare Recent Developments
  43. 8.8 Hisun Pharma
  44. 8.8.1 Hisun Pharma Company Information
  45. 8.8.2 Hisun Pharma Business Overview
  46. 8.8.3 Hisun Pharma Biosimilar Monoclonal Antibodies Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Hisun Pharma Biosimilar Monoclonal Antibodies Product Portfolio
  48. 8.8.5 Hisun Pharma Recent Developments
  49. 8.9 Torrent Pharmaceuticals
  50. 8.9.1 Torrent Pharmaceuticals Company Information
  51. 8.9.2 Torrent Pharmaceuticals Business Overview
  52. 8.9.3 Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Product Portfolio
  54. 8.9.5 Torrent Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Biosimilar Monoclonal Antibodies Value Chain Analysis
  2. 9.1.1 Biosimilar Monoclonal Antibodies Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Biosimilar Monoclonal Antibodies Sales Mode & Process
  6. 9.2 Biosimilar Monoclonal Antibodies Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Biosimilar Monoclonal Antibodies Distributors
  9. 9.2.3 Biosimilar Monoclonal Antibodies Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst